The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Setback for Gilead Hepatitis C Drug

February 21, 2012

Gilead Sciences Inc. on Friday announced that a majority of hepatitis C virus patients in one arm of a clinical trial relapsed after treatment with an experimental drug. Gilead obtained the drug, GS-7977, through its $11 billion purchase of Pharmasset last month. Gilead wants GS-7977 to serve as the anchor for what it hopes will be the first all-oral HCV treatment regimen. The relapses cited involved patients with HCV genotype 1 who previously had little or no response to an interferon-based regimen. The results suggest additional antiviral drugs may be needed, which Gilead said it will be exploring. GS-7977 has shown positive results with other HCV genotypes, including genotypes 2 and 3. Further trial results, including for treatment-naive HCV genotype 1 patients, will be released in the coming months.

Back to other news for February 2012

Adapted from:
Wall Street Journal
02.17.2012; Peter Loftus

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
More News and Research on Sovaldi (Sofosbuvir)

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: